Processa Pharmaceuticals, Inc.
PCSA
$2.55
-$0.01-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 55.36% | 60.66% | 11.24% | -0.94% | -11.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.37% | 1.87% | 28.19% | 1.33% | 10.74% |
| Operating Income | -35.37% | -1.87% | -28.19% | -1.33% | -10.74% |
| Income Before Tax | -23.10% | -1.53% | -30.68% | -3.96% | -13.46% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -23.10% | -1.53% | -30.68% | -3.96% | -13.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.10% | -1.53% | -30.68% | -3.96% | -13.46% |
| EBIT | -35.37% | -1.87% | -28.19% | -1.33% | -10.74% |
| EBITDA | -35.37% | -1.86% | -28.18% | -1.32% | -10.74% |
| EPS Basic | 92.33% | 93.00% | 74.96% | 73.08% | 54.52% |
| Normalized Basic EPS | 92.33% | 93.00% | 74.96% | 73.08% | 54.52% |
| EPS Diluted | 92.33% | 93.00% | 74.96% | 73.08% | 54.52% |
| Normalized Diluted EPS | 92.33% | 93.00% | 74.96% | 73.08% | 54.52% |
| Average Basic Shares Outstanding | 1,504.84% | 1,351.15% | 422.05% | 286.12% | 149.73% |
| Average Diluted Shares Outstanding | 1,504.84% | 1,351.15% | 422.05% | 286.12% | 149.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |